-
公开(公告)号：US20230123569A1
公开(公告)日：2023-04-20
申请号：US18073120
申请日：2022-12-01
Applicant: LegoChem Biosciences, Inc.
Inventor： Dae Yon Lee , Sang Eun Chae , Eun Mi Jung , Eun Hye Yang , Yoon Jeong Choi , Chul-Woong Chung , Ju Hyun Shin , Yun Ki Kim , Hyun Jin Kwon , Jeong Hee Ryu , Eun Hye Ban , Yong Zu Kim , Yeong Soo Oh , Jeiwook Chae
IPC: C07D413/14 , C07D239/42 , C07D401/14 , C07D413/12 , C07D471/04 , C07D471/10 , C07D498/10 , C07D519/00
Abstract: The present invention relates to novel compounds as autotoxin inhibitors for treatment and prophylaxis of conditions or a disorder caused by autotaxin activation or increased concentration of lysophosphatidic acid, and also a pharmaceutical composition containing the same.
The novel compounds of the present invention are autotoxin inhibitors, and by inhibiting the production of lysophosphatidic acid, they are useful for treatment or prophylaxis of cardiovascular disorder, cancer, metabolic disorder, kidney disorder, liver disorder, inflammatory disorder, nervous system disorder, respiratory system disorder, fibrotic disease, ocular disorder, cholestatic and other forms of chronic pruritus, or acute or chronic organ transplant rejection.-
公开(公告)号：US11548883B2
公开(公告)日：2023-01-10
申请号：US16098748
申请日：2018-05-15
Applicant: LegoChem Biosciences, Inc.
Inventor： Dae Yon Lee , Sang Eun Chae , Eun Mi Jung , Eun Hye Yang , Yoon Jeong Choi , Chul-Woong Chung , Ju Hyun Shin , Yun Ki Kim , Hyun Jin Kwon , Jeong Hee Ryu , Eun Hye Ban , Yong Zu Kim , Yeong Soo Oh , Jeiwook Chae
IPC: C07D413/14 , C07D239/42 , C07D401/14 , C07D413/12 , C07D471/04 , C07D471/10 , C07D498/10 , C07D519/00
Abstract: The present invention relates to novel compounds as autotoxin inhibitors for treatment and prophylaxis of conditions or a disorder caused by autotaxin activation or increased concentration of lysophosphatidic acid, and also a pharmaceutical composition containing the same.
The novel compounds of the present invention are autotoxin inhibitors, and by inhibiting the production of lysophosphatidic acid, they are useful for treatment or prophylaxis of cardiovascular disorder, cancer, metabolic disorder, kidney disorder, liver disorder, inflammatory disorder, nervous system disorder, respiratory system disorder, fibrotic disease, ocular disorder, cholestatic and other forms of chronic pruritus, or acute or chronic organ transplant rejection.-
公开(公告)号：US11413353B2
公开(公告)日：2022-08-16
申请号：US15779446
申请日：2016-11-23
Applicant: LegoChem Biosciences, Inc.
Inventor： Yong Zu Kim , Yeong Soo Oh , Jeiwook Chae , Ho Young Song , Chul-Woong Chung , Yun Hee Park , Hyo Jung Choi , Kyung Eun Park , Hyoungrae Kim , Jinyeong Kim , Ji Young Min , Sung Min Kim , Byung Soo Lee , Dong Hyun Woo , Ji Eun Jung , Su In Lee
Abstract: In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and an active agent. The antibody-drug conjugate may comprise a self-immolative group. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.
-
公开(公告)号：US20220226496A1
公开(公告)日：2022-07-21
申请号：US17607678
申请日：2020-04-29
Applicant: LEGOCHEM BIOSCIENCES, INC.
Inventor： Ho Young SONG , Yun-Hee PARK , Sang Eun CHAE , Ju Yuel BAEK , Kyung Eun PARK , Ju Young LEE , Su In LEE , Jeiwook CHAE , Chang Sun LEE , Yong Zu KIM
Abstract: The present invention relates to a ligand-drug conjugate including a ligand; a linker that is connected to the ligand by a covalent bond and has a tris structure represented by a specific structural formula; and an active agent connected to the linker by a covalent bond. In the ligand-drug conjugate, the active agent is bound by the tris structure of the linker, and thus a greater number of active agents can be connected through one linker. Accordingly, a greater number of active agents per antibody binding can be delivered to the target cell, and the drug and/or toxin can stably reach the target cell and effectively exert the drug efficacy.
-
公开(公告)号：US20170088614A1
公开(公告)日：2017-03-30
申请号：US15276209
申请日：2016-09-26
Applicant: LegoChem Biosciences, Inc.
Inventor： Yong Zu Kim , Yun Hee Park , Jeong Hee Ryu , Ho Young Song , Jeiwook Chae , Chul-Woong Chung , Ji Eun Jung , Hyo Jung Choi
CPC classification number: C07K16/2803 , A61K31/351 , A61K47/6803 , A61K47/6831 , A61K47/6849 , A61K47/6889 , A61K2039/505 , C07D301/10 , C07K2317/24 , C07K2317/73 , C07K2317/92 , C07K2317/94 , Y02A50/475
Abstract: In some aspects, the invention relates to an antibody-drug conjugate, comprising an anti-CD19 antibody; a linker; and an active agent. The antibody-drug conjugate may comprise a self-immolative group. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.
-
Patent Agency Ranking
公开(公告)号：US20140161829A1
公开(公告)日：2014-06-12
申请号：US14181648
申请日：2014-02-15
Applicant: LegoChem Biosciences, Inc.
Inventor： Yongzu Kim , Taekyo Park , Sungho Woo , Hyangsook Lee , Sunyoung Kim , Jongun Cho , Doohwan Jung , Youngun Kim , Hyunjin Kwon , Kyuman Oh , Yunseo Chung , Yun-Hee Park
IPC: A61K47/48
CPC classification number: A61K47/6811 , A61K47/549 , A61K47/55 , A61K47/65 , A61K47/6803 , A61K47/6817 , A61K47/6849 , A61K47/6851 , A61K47/6855 , A61K47/6859 , A61K47/6889 , C07K16/2863 , C07K16/32 , C12Q1/48
Abstract: The invention provides protein-active agent conjugates having an amino acid motif that can be recognized by an isoprenoid transferase. The invention also provides compositions containing the conjugates. The invention further provides methods for using the conjugates to deliver the active agent to a target cell, as well as methods for using the conjugates to treat a subject in need thereof (e.g., a subject in need of the active agent).
Abstract translation: 本发明提供了具有可被类异戊二烯转移酶识别的氨基酸基序的蛋白质 - 活性剂缀合物。 本发明还提供含有缀合物的组合物。 本发明还提供了使用结合物将活性剂递送至靶细胞的方法，以及使用缀合物治疗有此需要的受试者（例如需要活性剂的受试者）的方法。
-
公开(公告)号：US20220339291A1
公开(公告)日：2022-10-27
申请号：US16964965
申请日：2020-03-05
Applicant: LegoChem Biosciences, Inc. , Y-Biologics, Inc.
Inventor： Chang Sik Park , Min Ji Choi , Tae Ik Jang , Yun-Hee Park , Ho Young Song , Ju Yuel Baek , Sung Min Kim , Hyeun Joung Lee , Ju Young Lee , Hyoung Rae Kim , Kun Jung Lee , Yong Zu Kim , Chang Sun Lee , Jeiwook Chae , Sang Pil Lee , Ji-Young Shin , Sunha Yoon , Yunseon Choi , Jae Eun Park , Jisu Lee , Bum-Chan Park , Young Woo Park
Abstract: The present invention relates to new antibody-drug conjugates (ADCs) targeting DLK1, active metabolites of such ADCs, methods for preparation of such ADCs, uses for such ADCs in treatment and/or prevention of illnesses, and uses for such ADCs in production of drugs for treatment and/or prevention of diseases, more specifically, uses for such ADCs in producing drugs for treatment and/or prevention of proliferative and/or angiogenetic diseases, for example, cancer. More particularly, the present invention relates to an antibody-drug conjugate comprising an antibody binding with DLK1 or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same.
-
8.发明申请公开(公告)号：US20200172542A1
公开(公告)日：2020-06-04
申请号：US16783893
申请日：2020-02-06
Applicant: LegoChem Biosciences, Inc.
Inventor： Dae Yon Lee , Sang Eun Chae , Eun Mi Jung , Eun Hye Yang , Yoon Jeong Choi , Chul-Woong Chung , Ju Hyun Shin , Yun Ki Kim , Hyun Jin Kwon , Jeong Hee Ryu , Eun Hye Ban , Yong Zu Kim , Yeong Soo Oh , Jeiwook Chae
IPC: C07D471/04 , C07D498/10 , C07D519/00 , C07D471/10 , C07D413/14 , C07D413/12 , C07D403/14 , C07D401/14 , C07D513/04
Abstract: The present invention relates to novel compounds as autotoxin inhibitors for treatment and prophylaxis of conditions or a disorder caused by autotaxin activation or increased concentration of lysophosphatidic acid, and also a pharmaceutical composition containing the same.The novel compounds of the present invention are autotoxin inhibitors, and by inhibiting the production of lysophosphatidic acid, they are useful for treatment or prophylaxis of cardiovascular disorder, cancer, metabolic disorder, kidney disorder, liver disorder, inflammatory disorder, nervous system disorder, respiratory system disorder, fibrotic disease, ocular disorder, cholestatic and other forms of chronic pruritus, or acute or chronic organ transplant rejection.
-
公开(公告)号：US20180353611A1
公开(公告)日：2018-12-13
申请号：US16005245
申请日：2018-06-11
Applicant: LegoChem Biosciences, Inc.
Inventor： Yong Zu Kim , Tae Kyo Park , Sung Ho Woo , Sun Young Kim , Jung Un Cho , Doo Hwan Jung , Ji Young Min , Hyang Sook Lee , Yun Hee Park , Jeong Hee Ryu , Kyu Man Oh , Yeong Soo Oh , Jeiwook Chae , Ho Young Song , Chul-Woong Chung , Jeon Yang
IPC: A61K47/68 , C07K19/00 , C07K16/32 , C07D519/00 , C07D487/04 , C07D249/04 , A61K47/54 , A61K47/69 , A61K39/00
CPC classification number: A61K47/6871 , A61K47/50 , A61K47/549 , A61K47/6801 , A61K47/6803 , A61K47/6811 , A61K47/6813 , A61K47/6855 , A61K47/6889 , A61K47/69 , A61K2039/505 , C07D249/04 , C07D487/04 , C07D519/00 , C07K16/32 , C07K19/00 , C07K2317/24 , C07K2317/94
Abstract: Provided are compounds comprising a self-immolative group, and the compounds comprising a self-immolative group according to the present invention may include a protein (for example, an oligopeptide, a polypeptide, an antibody, or the like) having substrate-specificity for a target and an active agent (for example, a drug, a toxin, a ligand, a detection probe, or the like) having a specific function or activity.
-
公开(公告)号：US09919057B2
公开(公告)日：2018-03-20
申请号：US14865778
申请日：2015-09-25
Applicant: LegoChem Biosciences, Inc.
Inventor： Yong Zu Kim , Tae Kyo Park , Sung Ho Woo , Sun Young Kim , Jong Un Cho , Doo Hwan Jung , Jeon Yang , Ji Young Min , Hyang Sook Lee , Yun Hee Park , Jeong Hee Ryu , Kyu Man Oh , Yeong Soo Oh , Jeiwook Chae , Ho Young Song , Chul-Woong Chung
IPC: C07D309/10 , A61K47/48 , C07D249/04 , C07K19/00
CPC classification number: A61K47/6871 , A61K47/549 , A61K47/6801 , A61K47/6803 , A61K47/6811 , A61K47/6813 , A61K47/6855 , A61K47/6889 , A61K47/69 , A61K2039/505 , C07D249/04 , C07D487/04 , C07D519/00 , C07K16/32 , C07K19/00 , C07K2317/24
Abstract: Provided are compounds comprising a self-immolative group, and the compounds comprising a self-immolative group according to the present invention may include a protein (for example, an oligopeptide, a polypeptide, an antibody, or the like) having substrate-specificity for a target and an active agent (for example, a drug, a toxin, a ligand, a detection probe, or the like) having a specific function or activity.
-
-
-
-
-
-
-
-
-
Search Results
51
records
(took 0.021 seconds)
